From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world

doi:10.3748/wjg.v23.i29.5282

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 29

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (18335)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-6) series.

Item

Count

PDF

1404

WORD

331

HTML

12536

Figures (1-5)

377

Tables (1-6)

176

Sum=14824

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

516

Download

714

Sum=1230

Publishing Process of This Article

Item

Count

Browse

1123

Download

1158

Sum=2281

Aug 7, 2017 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (211)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Aug 7, 2017; 23(29): 5282-5294
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5282

Table 6 Treatment schedule proposed for hepatocellular carcinoma cirrhotic patients according to the Barcelona Clinic Liver Cancer classification system

Stage	Treatment intention	First/second choice
Stage A: early HCC
A1	Radical	Surgical resection
A2		Surgical resection ð OLT/percutaneous treatment
A3		OLT/percutaneous treatment (Ablation)
A4		OLT/percutaneous treatment (Ablation)
Stage B: intermediate HCC	Palliative¹	Trasanterial embolization (associated or not to percutaneous treatment)
Stage B: intermediate HCC	Palliative¹	Chemoembolization (TACE)
Stage C: advanced HCC	Palliative¹	New agents (Sorafenib)
Stage D: end-stage HCC	Symptomatic	Supporting treatment

¹In the setting of phase II investigations or randomized control trials. HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer.

Citation: Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, Athanasiou A, Moris D, Sakellariou S, Kykalos S, Tsourouflis G, Garmpi A, Delladetsima I, Kontzoglou K, Kouraklis G. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J Gastroenterol 2017; 23(29): 5282-5294
URL: https://www.wjgnet.com/1007-9327/full/v23/i29/5282.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i29.5282